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http://dxBackground: Penicillin is the most commonly reported allergy in cardiac surgical patients and a history of
penicillin allergy frequently results in the use of vancomycin for antibiotic prophylaxis. However, clinical
history is unreliable and true allergy is rare. Penicillin allergy testing has the potential to reduce vancomycin
use and indirectly the potential for selection of vancomycin-resistant organisms, a national priority.
Methods: After the publication of the 2007 Society of Thoracic Surgeons practice guideline report, we initiated
a penicillin allergy testing service for cardiac surgical patients in 2009. We sought to determine the true
incidence of penicillin allergy in the tested population, whether testing availability reduced vancomycin use
in those tested, and if vancomycin use was reduced in the entire cardiac surgical population as a whole.
Results:A total of 276 patients were skin tested for allergy to penicillin or cephalosporin. Testing recommended
no penicillin use in 13.8% of those tested giving a true penicillin allergy incidence of 0.9%. Only 24 of the 276
patients tested (9%) received vancomycin. However, given the small percentage of the total population that
underwent allergy testing, the overall use of vancomycin in the cardiac surgery practice was not reduced in
the posttesting period.
Conclusions: The true rate of contraindication to penicillin in a cardiac surgical population is very low.
Penicillin allergy testing can reduce vancomycin use in the tested population, but better means of conducting
the testing and making the results available are necessary to reduce unnecessary vancomycin use in a broader
cardiac surgical population. (J Thorac Cardiovasc Surg 2014;147:1931-5)P
MPenicillin is a commonly reported allergy and is important
in the care of cardiac surgical patients. Large studies
suggest a 10% self-reported rate in the general and surgical
population.1,2 Penicillin allergy is especially consequential
in the cardiac surgical patient, for whom effective antibiotic
prophylaxis against gram-positive organisms is critical
because staphylococci are the primary pathogens in both
sternal and vein donor site infections.3
Historically, patients reporting penicillin allergy have
often received vancomycin for antibiotic prophylaxis;
nevertheless, vancomycin use is not benign. There have
been long-standing concerns about renal toxicity with its
use, particularly in patents with preexisting renal dysfunc-
tion. Although renal toxicity has been greatly reduced
with improved dosing and formulations, it can still occur
when used in conjunction with other antibiotics, particu-
larly in the intensive care environment.4,5 Vancomycin
has also been associated with the red-man syndrome, which
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The Journal of Thoracic and Carfrequently, hypotension.6,7 The red-man syndrome, an
anaphylactoid reaction, has been associated with increased
histamine levels and the rapid intravenous infusion of van-
comycin.8 In cardiac surgical patients, the hypotension
associated with vancomycin administration in the preoper-
ative period has sometimes resulted in cardiovascular
collapse.9,10 Perhaps more salient is the effect of
vancomycin overuse on the selection of vancomycin-
resistant enterococcus (VRE) and Staphylococcus
aureus.11,12 VRE is now one of the most common causes
of nosocomial infection and has been associated with
significant increase in mortality and hospital costs.13,14
Although vancomycin-resistant Staphylococcus aureus
(VRSA) is still rare in the United States, vancomycin-
intermediate Staphylococcus aureus (VISA) has become
more prevalent and is an increasing cause of concern.15-18
Both recent exposure to vancomycin and intensive care
unit stay have been independently associated with
decreased susceptibility to vancomycin in patients with
methicillin-resistant Staphylococcus aureus (MRSA).19
For more than a decade, there have been recommendations
against the routine use of vancomycin for antibiotic prophy-
laxis in surgery.20 Prevention of multiantibiotic resistance is
critical in hospitals providing cardiac surgical care because
most of these infections are acquired in the hospital.14 Thus,
the nosocomial risk to cardiac surgical patients can be
reduced by judicious choice of antibiotic.
Although the emergence of VRE and VISA has resulted
in national and institutional efforts to reduce vancomycin
overuse, the increasing prevalence of MRSA has led to adiovascular Surgery c Volume 147, Number 6 1931
Abbreviations and Acronyms
MRSA ¼ methicillin-resistant Staphylococcus
aureus
VISA ¼ vancomycin-intermediate Staphylococcus
aureus
VRE ¼ vancomycin-resistant enterococcus
VRSA ¼ vancomycin-resistant Staphylococcus
aureus
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Mdramatic increase in the use of vancomycin.21 Thus, vanco-
mycin use as antibiotic prophylaxis is recommended only at
institutions where there is a high prevalence of MRSA
(class IIB recommendation).22
This issue has been pressing enough in the cardiothoracic
surgery community that a national cardiac surgical task
force on the use of antibiotic prophylaxis addressed this
issue in their 2007 report.22
Because the primary driver of vancomycin use in cardiac
surgery is penicillin allergy,22 vancomycin use in the car-
diac surgical population could be greatly reduced if clinical
reporting of penicillin allergy could be better addressed.
However, patient history of penicillin allergy is problem-
atic. Previous exposure is often remote, the reaction un-
known or vague, and whether the symptom came from an
associated condition or the penicillin itself can rarely be
sorted out by clinical history alone.23 Therefore, because
of the widely reported, but likely overestimated, 10% inci-
dence of crossreactivity to cephalosporins in patients with
penicillin allergy,24,25 the easiest route for a busy cardiac
surgical practice is to use vancomycin for antibiotic
prophylaxis to obviate the potential morbidity associated
with a severe allergic reaction.26
Following the publication of the 2007 Society of
Thoracic Surgeons Practice Guideline report,22 we decided
to initiate a mechanism for preoperative skin testing in car-
diac surgical patients who self-reported penicillin allergy.
We recognized the value of this for patient care, not only
for the perioperative cardiac surgical experience but also
to guide future antibiotic use in this population over the
course of their lives. We report here 3 observations: (1)
the true incidence of penicillin allergy in patients who
self-report; (2) whether penicillin skin testing changed
antibiotic use in those tested; and (3) whether or not the
availability and reporting of skin testing reduced the use
of vancomycin in this cardiac surgical population.PATIENTS AND METHODS
Aconsult servicewithin theDepartment ofAllergy existed before begin-
ning the initiative in cardiac surgery. An electronic mechanism for ordering
penicillin skin testing is available to all providers atMayoClinic-Rochester.
In the fourth quarter of 2007, the divisions of Cardiology and Cardiovascu-
lar Surgery were made aware of the availability of this outpatient service,1932 The Journal of Thoracic and Cardiovascular Surand providers were encouraged to request skin testing in anyone scheduled
for cardiac surgery with a clinical history of penicillin allergy. This quality
improvement project was initiated on February 25, 2009.
On referral for penicillin skin testing, a clinical history of the reactionwas
obtained. Patientswith a history suggestive of an anaphylactic, IgE-mediated
reactionwere not tested and assumed to be positive.Given the primary use of
cefazolin for antibiotic prophylaxis and potential crossreactivity, all other
patients were tested for allergy to both penicillin and cefazolin.
Penicillin Skin Testing
Penicillin allergy skin testing was conducted using benzylpenicilloyl
polylysine, penicillin G potassium (Pfizerpen; Pfizer, New York, NY) and
penicillate, as previously reported.27,28 A skin prick test with 6 mg/mL
histamine or 0.1 mg/mL histamine administered intradermally was used
as the positive control, and the negative control was phosphate-buffered
saline. Skin prick tests were performed on the volar surface of the forearm
with each of the penicillin and control reagents. The skin test sites were
examined after 15 minutes. A positive test result was defined as a wheal
of 3 3 3 mm or greater with a surrounding zone of erythema.29 Patients
with negative prick test results for penicillin underwent intradermal testing.
Intradermal skin tests were also performed on the volar surface of the
forearm. The test reagents were injected intradermally to produce an initial
wheal of 23 2 mm. The skin test sites were examined after 15 minutes. A
positive interdermal test was defined as awheal of 33 3mmor greater with
a surrounding zone of erythema.30 Patients with a wheal but without a flare
on the penicillin skin test (skin prick and intradermal) were considered
to be equivocal. Allergy skin testing was performed in a place where
resuscitation equipment was available in case of anaphylaxis.30
This study was approved by the Mayo Foundation Institutional Review
Board. History of a self-reported penicillin allergy within 30 days of oper-
ation of all patients undergoing cardiac surgery requiring cardiopulmonary
bypass was queried using the Mayo Clinic Life Sciences System database.
The incidence of self-reported penicillin allergy was then determined for
the period from February 25, 2009, to December 31, 2012.
To determinewhether skin testing changed the choice of antibiotic in the
operating room, an electronic query of the anesthesia record was initiated.
We queried the use of vancomycin for 2008 to 2012 and crossreferenced
that with cardiopulmonary bypass in the intraoperative period. These re-
sults were then crossreferenced with those patients having skin testing.
This allowed us to determine the percentage of patients receiving vancomy-
cin before (2008) and after the skin testing effort was initiated. The anes-
thetic records of the subset of patients who received a ‘‘no
cephalosporin’’ recommendation after skin testing and who did not receive
vancomycin intraoperatively were reviewed to determine which antibiotic
was administered.
RESULTS
In 2008, 2330 patients underwent cardiac surgery at
Mayo Clinic-Rochester. A total of 176 patients (7.1% of pa-
tients) received vancomycin as antibiotic prophylaxis
before incision. During the reporting period of February
25, 2009, to December 31, 2012, 8914 patients underwent
cardiac surgery with cardiopulmonary bypass; of those,
276 patients underwent preoperative skin testing. History
of a penicillin allergy was present in 578 of 8914 patients
(6.5%) within the 30 days before cardiac surgery. Based
on the self-reported penicillin allergy incidence of 6.5%
at our institution, our 276 tested patients represent a cardiac
surgical population of approximately 4246. From this, it can
be inferred that only 48% of patients who reported peni-
cillin allergy were tested.gery c June 2014
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Therewere 132men and 144women tested. The clinical his-
tory of penicillin allergy included rash or hives in 44.6%,
unknown in 13.8%, angioedema in 2.5%, and swelling in
8.8%. Other miscellaneous reactions included nausea, joint
pain, diarrhea, emesis, vertigo, leg paralysis, shortness of
breath, and, in 1 case, the patient’s allergy was based on
the history of a parent with a syncopal episode.
Of the 276 patients referred for testing, 240 reported a spe-
cific allergy to penicillin, 33 described an antibiotic allergy
to amoxicillin or amoxicillin/clavulanic acid, 2 reported an
allergy to cefazolin or another cephalosporin, and 1 patient
an allergy to both amoxicillin and a cephalosporin. Of the
36 patients reporting an allergy to an antibiotic other than
penicillin, 27 described rash or hives, 3 experienced nausea,
1 had dyspnea, and 5 had unknown reactions.
Penicillin testing in cardiac surgical patients began at our
institution on February 25, 2009. Based on positive testing
results, the recommendation of the allergist was to avoid
penicillin in 22 of 260 patients (8.5%). Five tests were
equivocal, and in 11 patients testing was not performed
because of a history of anaphylaxis (7 patients), history of
severe skin sloughing (2 patients), and patient refusal (2 pa-
tients). Assuming that all the patients testing positive,
equivocal, or who were not tested were penicillin allergic
(38 of 276 patients), the incidence of true penicillin allergy
among patients reporting allergy and presenting for peni-
cillin testing was 13.8% (Figure 1). For these 38 patients,FIGURE 1. With an incidence of patient-reported penicillin allergy of
6.5% at our institution, a population of 276 referred for allergy testing rep-
resents a cardiac surgical sample of approximately 4246. The recommen-
dation ‘‘do not use penicillin’’ because of true allergy, equivocal testing,
or history indicating previous severe reaction was given for 38 patients.
For cephazolin, ‘‘avoid’’ was the recommendation in 40 patients.
The Journal of Thoracic and Carthe male to female ratio was 23:15. Based on a self-
reported penicillin allergy incidence of 6.5% in our prac-
tice, our 276 tested patients can be considered to represent
a cardiac surgical population of approximately 4246 pa-
tients. Thus, 38 positive tests in a population of 4246 would
represent a true allergy rate of 0.9%. Similarly, a 13.8%
positive rate in 6.5% of the population represents a true al-
lergy rate of 0.9%. This incidence of true penicillin allergy
closely parallels what has been reported in the general pop-
ulation, as determined by a positive skin test.31
For cefazolin, 24 of 260 patients tested positive, 5 tests
were equivocal, and 11 were not tested as mentioned earlier.
Thus, 40 of 276 patient referrals (14.5%) resulted in a ‘‘no-
cefazolin’’ recommendation, again representing about
0.9% of the predicted cardiac surgical population sampled.
Allergy consultation concluded that 27 of 276 patients were
allergic to both penicillin and cefazolin, 13 of 276 had only
a cefazolin allergy, and 11 of 276 had a penicillin allergy but
showed no reaction to cefazolin (Figure 1).P
MVancomycin Use
Of the 276 patients referred for skin testing, only 24 (9%)
subsequently received vancomycin in the operating room, a
91% reduction, had it been administered solely on the basis
of penicillin allergy. Patients with a ‘‘no-cefazolin’’ recom-
mendation after skin testing who did not receive vancomy-
cin were administered clindamycin intraoperatively.
The availability of penicillin skin testing did not change
the use of vancomycin across the cardiac surgical practice,
presumably because of underutilization of testing in pa-
tients with self-reported penicillin allergies or use of vanco-
mycin for reasons other than penicillin allergy. In the
baseline period of 2008, 7.1% (166 of 2330) cardiac surgi-
cal patients received vancomycin. Between initiation of
testing in February of 2009 and December 31, 2009,
6.9% of patients received vancomycin as antibiotic prophy-
laxis, and in 2010, 2011, and 2012, 7.2%, 7.1%, and 7.9%,
respectively, of patients received vancomycin (Table 1).
Thus, the availability and reporting of skin test results did
not reduce the overall use of vancomycin in the entire car-
diac surgical population between 2008 and 2010.COMMENT
Between February 25, 2009, and December 31, 2012,
8914 patients underwent cardiac surgery at Mayo Clinic-
Rochester. The incidence of self-reported penicillin allergy
among these patients was 6.5%, which is consistent with re-
ports on very large populations (>10,000) of surgical pa-
tients.2 Based on our incidence of self-reported penicillin
allergy, we would have anticipated 578 patients would
have self-reported penicillin allergy; however, only 276 pa-
tients were evaluated at the allergy clinic, half of what
would be anticipated.diovascular Surgery c Volume 147, Number 6 1933
TABLE 1. Vancomycin use in cardiac surgery before (2008) and after
initiation (February 25, 2009) of penicillin allergy testing
Cases with
cardiopulmonary
bypass
Received
vancomycin
Percent
(%)
2008 (baseline) 2330 166 7.1
2009 (y 1) (start February 25) 1990 137 6.9
2010 (y 2) 2446 177 7.2
2011 (y 3) 2253 160 7.1
2012 (y 4) 2225 176 7.9
No significant differences were found between years.
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MThere are multiple reasons why a greater portion of the
cardiac surgical population did not undergo skin testing.
These are likely to include
1. provider awareness of the availability or importance of
penicillin skin testing
2. the testing clinic being geographically remote from the
cardiac surgery clinic
3. challenges in getting the penicillin skin testing sched-
uled (many patients having next-day surgery)
4. limited hours of testing availability
5. patient choice not to undergo skin testing
Nonetheless, there is no reason to think that the results in
the tested population, representing approximately 4246 pa-
tients, is not representative of the broader cardiac surgical
population. This is reinforced by our reported true allergy
rate of 0.9%, which is in close alignment with results in
large population studies.1,2,31
Other observations were that 27 of 38 patients who were
allergic to penicillin also had a positive skin test to cefazolin,
which is much higher than would be predicted from the ex-
isting literature.25,32 We also found, in contrast to an earlier
report, that there was no predominance of penicillin allergy
among women.33 Furthermore, other than anaphylaxis and
severe skin sloughing, which resulted in avoidance of al-
lergy testing, a clinical history of penicillin allergy was
not predictive of a positive result to skin testing.
The Society of Thoracic Surgeons practice guidelines22
and others34 clearly delineate the issues around antibiotic
prophylaxis in cardiac surgery, including the specific Cen-
ters for Disease Control and prevention guidelines on use
of vancomycin by the Healthcare Infection Control Prac-
tices Advisory Committee (1995). The report also describes
the superiority of cefazolin to vancomycin as the agent of
choice34 and makes recommendations on the therapeutic
strategy in patients based on a clinical history of penicillin
allergy. The report describes the appropriate broader use of
vancomycin in patients who are allergic to penicillin when
there is an increased institutional risk of MRSA.22
Because of the unreliability of the clinical history in
penicillin allergy,24,31,35 we attempted to go a step
further by advocating skin testing for the cardiac surgical1934 The Journal of Thoracic and Cardiovascular Surpopulation. Results here describe modest success with
that effort.
This report clearly supports a reduction in the use of van-
comycin as a prophylactic agent in patients reporting peni-
cillin allergy. The true penicillin allergy rate by skin testing
is only 0.9% of the cardiac surgical population. If we are
conservative (including true positives, ambiguous results,
and those not tested as true allergy), only about 14% of
those with a self-reported allergy are actually penicillin
allergic. Deciding to use vancomycin from the clinical his-
tory alone will lead to overuse.
We were effective in reducing vancomycin use in those
tested. Of 276 patients tested, only 9% received vancomy-
cin in the operating room, a much lower rate than would
have occurred on the basis of allergy history.
It would be desirable to determine the cost-benefit ratio
for penicillin skin testing, however that is beyond the scope
of this report. The actual cost of the skin testing would have
to be compared with any cost savings obtained from a
reduction in the incidence of VRE or VRSA in the intensive
care unit. This is beyond what is possible in a single site
report.
Limitations of this study include all those inherit to a
retrospective series including potential charting inaccura-
cies and unclear reasons for management decisions. In addi-
tion, specific reasons why patients with self-reported
penicillin allergies did not undergo penicillin skin testing
cannot be determined. Although a reduction in intraopera-
tive vancomycin use for the entire population was not
observed after implementation of penicillin skin testing,
we attribute this to the observation that most patients with
a self-reported penicillin allergy did not undergo testing
and the use of vancomycin for reasons other than penicillin
allergy. The study was not designed to measure the adverse
effects of unnecessary vancomycin administration such as
an increased prevalence of resistant bacterial strains.
It is clear that penicillin allergy testing adds value and can
reduce vancomycin use to less than what can be accom-
plished with guidelines alone. However, for clinicians to
take full advantage of this resource, there must be a clear
understanding of the value of skin testing and its impact
on reducing vancomycin use. To reduce population-based
issues such as vancomycin resistance, it is incumbent to
build systematized mechanisms for testing and clear and
effectiveways to convey the results to providers. This report
is an attempt to begin to move the discussion in that
direction.References
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